In this study, we obtained a cutoff value of Ki67 of 35% by receiver operating characteristic curve (Figure 6).The results found that the mOS and mPFS of patients with lower Ki67 expression who received 6 cycles of TMZ treatment was significantly longer than those with higher Ki67 expression (mOS: 19.80 months vs. 13.80 months, HR = 0.36, 95% CI: 0.18 ~ 0.70, P < 0.001; mPFS: 11.50 months vs. 8.80 months, HR = 0.43, 95% CI:0.22 ~ 0.82, P = 0.004), which suggested that GBM patients with lower Ki67 expression were more sensitive to TMZ chemotherapy than those with higher expression of Ki67. This evidence concerns the gene MKI67 and glioblastoma.